Press Releases
MAS-EPSILON Announces Licensing of
SAAM II -
Statistical Analysis and Modeling Software
Licensed from the University of Washington Office of
Technology Transfer, MAS-EPSILON plans to support
current +5000 user group with ongoing educational
webinars, NIH courses and upgrade software to using
current robust statistical analysis and graphics tools.
More
MAS-EPSILON Announce First FDA-Accepted
Type 1 Diabetes Metabolic Simulator
MAS-Epsilon announce
the availability of the only diabetes simulation
technology accepted by the U.S. Food and Drug
Administration (FDA) as a substitute for animal trials
in the pre-clinical testing of control strategies in the
Type 1 Diabetes Metabolic Simulator (T1DMS).
The T1DMS provides a safe, interactive modeling
and learning environment for the
research/training/education of study investigators,
healthcare providers and patients and families managing
their disease towards improved glucose control.
More
NICE-SUGAR
Survey
Following the completion of the first survey of glycemic
control, the report of the NICE-SUGAR Study in critically ill
hospitalized patients determined there was “no difference” in
ICU morbidity and mortality among patients randomized to tightly
controlled blood glucose compared to moderately controlled blood
glucose causes further confusion regarding how to best manage
inpatient hyperglycemia.7 Additionally, the release of the ADA/AACE
Consensus panel statement8 advised a higher and wider target
range for glucose control to avoid hypoglycemia. This follow up
survey was distributed to determine how hospitals interpreted
this new information, and actions taken in response.
Click
Here to View the Survey
Tight
Glycemic Control Survey
For nearly a decade, hospitals have worked to establish glycemic
control programs to better manage inpatient blood glucose,
primarily in the intensive care unit. Several randomized
controlled trials, 1, 2, 3 and extensive anecdotal and
observational data4, 5, 6 have demonstrated a consistent, direct
relationship between hyperglycemia and increased complications
and mortality. This survey was conducted to determine the
current state of glycemic control in U.S. hospitals. A summary
of the results will be posted when completed.
Click
Here to View the Survey
FDA Clears
GlucoStabilizer Intravenous
Insulin Dosing Software
CHARLOTTESVILLE, VA, October 17, 2007 – Medical Decisions
Network (MDN) announces Food and Drug Administration 510(k)
clearance for the company’s GlucoStabilizer IV Insulin Dosing
Software. GlucoStabilizer software is used by hospital nurses to
quickly and accurately calculate the dosage of intravenous
insulin administered to patients with elevated levels of blood
glucose, the simple form of sugar the body converts to energy
for survival.
Epsilon I
ntroduces
Continuous Glucose - Error Grid Analysis (CG-EGA)
The
CG-EGA is a Windows-based, statistical program designed for use
by the diabetes technology industry in the evaluation of
continuous glucose monitoring (CGM) devices. The CG-EGA is a logical extension of the original
error grid analysis (EGA), which was developed for assessing the
clinical accuracy of patient-determined blood glucose values
using either estimation or self-monitoring blood glucose
systems. The CG-EGA is based upon the premise that information
being generated by a monitoring system should be reliable enough
to result in clinically accurate decision making by the user.
Medical Automation Systems
Acquires The Epsilon Group
In November 2004, The Epsilon Group was acquired by Medical
Automation Systems, Inc. (MAS). MAS is the leader in
point-of-care informatics for hospitals and has placed it's
RALS® data management technology in nearly 1,000 hospitals
across the United States. The acquisition enables The Epsilon
Group to provide MAS with the ability to offer customized
post-marketing studies as well as enhanced, comprehensive
services to it's existing customer base
Back to Top
